In our study, subjects with FLI ≥ 60 had a significantly higher frequency of previous cardiovascular disease and MetS as well as significantly increased plasma concentrations of triglycerides, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as compared to subjects without suspected NAFLD (FLI < 60). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.